Significant dose Escalation of Idarubicin in the treatment of aggressive Non- Hodgkin Lymphoma leads to increased hematotoxicity without improvement in efficacy in comparison to standard CHOEP-14: 9-year follow up results of the CIVEP trial of the DSHNHL

SpringerPlus

Table 1 CIVEP dose levels as described in Materials and Methods, 64 patients were assigned to different levels of Idarubicine according to a modified Storer up-and-down design

CIVEP dose levels	I-11	I-12	I-13	I-14	I-15	I-16b	I-16c	Application
Cyclophosphamide	750	750	750	750	750	750	750	mg/m² i.v. d1
Idarubicin	11	12	13	14	15	16	16	mg/m² i.v. d1
Vincristine	2	2	2	2	2	2	2	mg (abs.) i.v.d1
Etoposide	100	100	100	100	100	100 bolus	100 civ	mg/m² i.v d1 - 3
Prednisone	100	100	100	100	100	100	100	mg p.o. d1 – 5
G-CSF	300/480	300/480	300/480	300/480	300/480	300/480	300/480	μg/d s.c. d5 - 13
Patient# allocated excluded	1	3	4	12	20	10	14
Patient# allocated excluded		1	1	2	2	2	1

At dose level 16, patients were assigned to either bolus or continuous i.v. infusion of Etoposide.